Septerna (NASDAQ:SEPN) Lowered to Sell Rating by Wall Street Zen

Key Points

• Septerna has been downgraded from a "hold" to a "sell" rating by Wall Street Zen, indicating a negative outlook for the company's stock.
• Despite the downgrade, consensus ratings from other analysts show that Septerna still holds a "Moderate Buy" with an average target price of $26.75.
• In its most recent quarterly earnings report, Septerna reported a loss of $(0.56) EPS, significantly missing estimates, with a net margin of -12,053.03%.

Septerna (NASDAQ:SEPN - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Saturday.

SEPN has been the topic of a number of other research reports. Wells Fargo & Company increased their price objective on shares of Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a research report on Friday, May 16th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price target on shares of Septerna in a research report on Friday, September 5th. Finally, HC Wainwright reiterated a "buy" rating and issued a $26.00 price target on shares of Septerna in a research report on Thursday, August 21st. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $26.75.

Septerna Price Performance

Septerna stock traded up $1.55 during midday trading on Friday, reaching $15.94. 259,044 shares of the company traded hands, compared to its average volume of 217,588. The firm has a market capitalization of $710.61 million and a price-to-earnings ratio of -1.58. The business has a 50 day moving average of $12.74 and a two-hundred day moving average of $9.65. Septerna has a 12 month low of $4.17 and a 12 month high of $28.99.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.51). The company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $22.50 million. Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. As a group, equities analysts forecast that Septerna will post -7.11 EPS for the current year.

Institutional Trading of Septerna

Several institutional investors and hedge funds have recently modified their holdings of the company. Rangeley Capital LLC raised its position in shares of Septerna by 10.7% during the 2nd quarter. Rangeley Capital LLC now owns 58,605 shares of the company's stock valued at $619,000 after purchasing an additional 5,655 shares during the period. Perceptive Advisors LLC bought a new stake in shares of Septerna during the 2nd quarter valued at $5,723,000. Boothbay Fund Management LLC bought a new stake in shares of Septerna during the 2nd quarter valued at $255,000. Bank of America Corp DE raised its position in shares of Septerna by 758.3% during the 2nd quarter. Bank of America Corp DE now owns 99,213 shares of the company's stock valued at $1,049,000 after purchasing an additional 87,654 shares during the period. Finally, VR Adviser LLC bought a new stake in shares of Septerna during the 2nd quarter valued at $5,713,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.